← Today’s ReceiptsOfficial public filing linked
Public-record receiptD-RIOfficial filing linked
Sheldon Whitehouse disclosed BUY $LLY
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$15K – $50K
Filed
2024-11-07
Trade date
2024-10-30
Disclosure lag
8 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 8 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $15K – $50K, which is the public reporting band rather than an exact profit or loss figure.
410 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Sheldon Whitehouse, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Market context is shown as a post-trade reference (-13.8% versus SPY); it is not a trading recommendation.
Source
Official filing ↗
Source: official House/Senate financial disclosure record · filing ID a3fd3dbc-8c32-476a-85eb-67ee0ce304cb · filed 2024-11-07 · disclosed 8d after transaction
Market context
Eli Lilly and Company
Sector: Healthcare
Vs SPY: -13.8%
Factual flags
- 10 nearby same-ticker disclosures in the surrounding 30-day window.
- 12 trades filed on 2024-11-07 (batch dump)
- Sits on committee with jurisdiction over healthcare/pharma sector — traded LLY on 2024-10-30
Member trail
Sheldon Whitehouse
U.S. Senate · RI
Senate Committee on Environment and Public WorksSenate Committee on FinanceSenate Committee on the BudgetSenate Committee on the JudiciaryUnited States Senate Caucus on International Narcotics ControlCommission on Security and Cooperation in Europe
Ticker trail
$LLY
Eli Lilly and Company
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.